Literature DB >> 3300815

Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

S J Forman, M R O'Donnell, A P Nademanee, D S Snyder, P J Bierman, G M Schmidt, J L Fahey, A S Stein, P M Parker, K G Blume.   

Abstract

We report the treatment outcome of allogeneic bone marrow transplantation in ten patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Six patients are alive and well for 6 to 30 months (median 19 months) after transplantation. Four patients died with transplant related complications. In view of the poor prognosis associated with this disease, marrow ablation followed by allogeneic or syngeneic marrow grafting may be the preferred treatment modality if a suitable marrow donor is available.

Entities:  

Mesh：

Year:  1987        PMID： 3300815

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.

Authors:  Prakash Satwani; Harland Sather; Fevzi Ozkaynak; Nyla A Heerema; Kirk R Schultz; Jean Sanders; John Kersey; Virginia Davenport; Michael Trigg; Mitchell S Cairo
Journal:  Biol Blood Marrow Transplant       Date:  2007-02       Impact factor: 5.742

3.  Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia.

Authors:  G Götz; H J Weh; T A Walter; R Kuse; K Kolbe; G Dölken; K P Hellriegel; D Hoelzer; D K Hossfeld
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

Review 4.  Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.

Authors:  Hiroatsu Iida; Hiroshi Sao; Kenjiro Kitaori; Seiichi Gotoh; Makoto Yazaki; Seiji Kojima; Atsushi Wakita; Yasuo Morishima; Yoshihisa Kodera; Yoshihisa Morishita
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 5.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

Review 6.  Bone marrow transplantation for acute lymphoblastic leukemia (ALL).

Authors:  H M Lazarus; J M Rowe
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

7.  High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study.

Authors:  R Scherrer; P Bettelheim; K Geissler; U Jäger; P Knöbl; P A Kyrle; K Laczika; G Mitterbauer; E Neumann; B Schneider
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

8.  Chemotherapy versus bone marrow transplantation in childhood acute lymphoblastic leukaemia. BFM Study Group.

Authors:  W Ebell; A Reiter; H Riehm
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

9.  Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.

Authors:  Ginna G Laport; Joseph C Alvarnas; Joycelynne M Palmer; David S Snyder; Marilyn L Slovak; Athena M Cherry; Ruby M Wong; Robert S Negrin; Karl G Blume; Stephen J Forman
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

10.  In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT.

Authors:  H Martin; J Atta; J Bruecher; S Elsner; C Schardt; M Stadler; H von Melchner; D Hoelzer
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.